Sequenom Files Patent Infringement Lawsuit in Australia

SAN DIEGO, June 7, 2016 /PRNewswire/ -- Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it filed a patent infringement lawsuit in Australia. The patent relates to the detection of cell-free fetal DNA for non-invasive prenatal testing (NIPT). 


The lawsuit was filed against Sonic Healthcare, Australian Clinical Labs and Ariosa Diagnostics, Inc. in the Australian Federal Court. The suit accuses Sonic Healthcare and Australian Clinical Labs' use of the Harmony™ NIPT test supplied by Ariosa of infringing Australian Patent 727,919.  Sequenom is seeking all available remedies, including damages (or an account of profits) and ­­­­­­­­orders of restraint.

"Sequenom established the NIPT market with the introduction of the MaterniT® 21 laboratory-developed test in 2011 and has developed pioneering intellectual property in the NIPT testing field," said Dirk van den Boom, Ph.D., President and CEO of Sequenom.  "In 2014 we entered into an agreement with Illumina, Inc. to pool our NIPT intellectual property and allow for easier access to both parties' NIPT technology by healthcare providers and their patients.  Currently, over 45 healthcare organizations globally have licensed the intellectual property in order to develop and deliver the highest quality NIPT tests.  We are committed to preserving the value of the intellectual property of the patent pool for the benefit of our licensees, and this lawsuit adds to suits already filed in the U.K. and in Europe."

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier lives through the development of innovative products and services. The Company serves patients and physicians by providing early patient management information.  To learn how Sequenom is interpreting the genome to improve your life, visit

About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT®, HerediT® UNIVERSAL, MaterniT® GENOME, MaterniT® 21 PLUS, NextView®, SensiGene® and VisibiliT™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists. Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. Visit and follow @SequenomLabs.

SEQUENOM®, HerediT®, MaterniT®, NextView®, SensiGene®, VisibiliT and Sequenom Laboratories are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Logo -


SOURCE Sequenom, Inc.

For further information: Sequenom Contacts, Paul Goodson, Senior Director, Investor Relations and Corporate Communications, Sequenom, Inc. 858-202-9427,

print email rss pdf